Monday, June 13, 2022

Ainnocence Applies AI To Drug Discovery

A new, San Diego-based biotech startup, Ainnocence launched today, saying that it is focused on using life-sciences knowledge and advanced computational techniques to accelerate the design of small-molecule, antibody, and other complex therapeutic modalities. The company is led by CEO Lurong Pan. According to Ainnocence, its first products are SentinusAI, a product that performs antibody design and optimization based solely on sequences, and CarbonAI, a small-molecule and PROTAC design engine for multi-objective pharmacological profile optimization. The company did not say how it is funded.